Autolus
London
About Autolus
Autolus Therapeutics is working on next-generation programmed T cell treatments for the treatment of cancer. The company's pipeline includes Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Autolus was established in 2014 by Tim Funnell and Martin Pule in London, England.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 501 – 1,000
- Estimated revenue: $10K – $50K
- Total funding: $1.1B
- Funding stage: IPO
- Last round: Post-IPO Equity (Feb 2024)
- Ticker: nasdaq:AUTL
- Website: autolus.com
- Phone: +44 (0)20 3829 6230
Industries & Categories
Biopharma, Biotechnology, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/autolus-76300 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.